OpportunityAnalyzer: Osteoarthritis - $1.7 Billion Opportunity Analysis and Forecasts to 2026 - ResearchAndMarkets.com

DUBLIN--()--The "OpportunityAnalyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2026" drug pipelines has been added to ResearchAndMarkets.com's offering.

Osteoarthritis (OA) market is expected to increase at a compound annual growth rate (CAGR) of 8.1%

'OpportunityAnalyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2026', provides overview of OA, including epidemiology (separation between symptomatic and radiographic patients), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

The US contributed 68% of the market share in 2016, which is linked to the large OA population and high drug prices in this market. Multiple biologic drug launches are expected during the forecast period and will lead to rapid market growth in the US and Japan, posting CAGRs of 9.2% and 6.1%, respectively. The 5EU will have the slowest market growth (at a CAGR of 4.8%), as only two drugs are expected to launch in this region during the forecast period. Although both therapies are biologics, they will likely have a slow uptake due to the associated high price.

The main drivers of growth in the OA market include the increasing numbers of OA cases and the expected launches of multiple biologic drugs, which are forecast to radically change the OA market and add over $1.7Billion in sales to the market in 2026.

Current OA therapy landscape offers a large opportunity for pharmaceutical companies to develop drugs with new MOAs and disease-modifying effects as the pathophysiology of OA is elucidated and new targets identified. This opportunity could be exploited by supporting academic institutions in their ongoing efforts to identify new disease targets and biomarkers. Companies may also consider in-licensing pipeline products with novel analgesic mechanisms or disease-modifying potential.

Summary

  • OA Market Expected to Experience Strong Growth from 2016-2026
  • Drug Development Focused on Analgesics with Novel MOAs and DMOADs
  • Clinical Unmet Need Will Remain Largely Unfulfilled
  • The OA Market Provides an Abundance of Opportunities for the Development of Novel Analgesics and DMOADs
  • Anti-NGFs Are Likely to Become the Most Attractive New Treatment Option
  • What Do Physicians Think?

Key Topics Covered:

1 Table of Contents

2 Osteoarthritis: Executive Summary

3 Introduction

4 Disease Overview

5 Epidemiology

6 Current Treatment Options

7 Unmet Needs and Opportunity Assessment

8 Research & Development Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Appendix

Companies mentioned in this report:

  • Ampio Pharmaceuticals
  • Cara Therapeutics
  • Cellular Biomedicine Group
  • Centrexion Therapeutics
  • Eli Lilly
  • Flexion Therapeutics
  • Healthcare Life Sciences
  • Kolon Life Sciences
  • Mitsubishi Tanabe Pharma
  • Mundipharma
  • Ono Pharmaceutical

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/tt688h/opportunityanalyze?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Musculoskeletal Disorders Drugs